ATRIPLA — FDA application NDA021937

Application NDA021937 · type NDA · FDA status: approved · original approval 2006-07-12

Listed sponsor: GILEAD SCIENCES · GILD company profile · exact_unique

Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.

FDA application facts

Product	FDA-listed trade name	Active ingredient	Dosage form	Route	Strength	Marketing status	TE code	RLD
001	ATRIPLA	EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE	TABLET	ORAL	600MG;200MG;300MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	Discontinued	not listed	Yes

Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.

Listing	Product	Descriptive date	Flags/code
Patent 9018192	001	listed patent expiry date: 2026-06-13	U-750
Patent 9018192	001	listed patent expiry date: 2026-06-13	U-1170
Patent 9545414	001	listed patent expiry date: 2026-06-13	drug product, U-1170
Patent 9545414	001	listed patent expiry date: 2026-06-13	drug product, U-750
Patent 8598185	001	listed patent expiry date: 2029-04-28	drug product

Patent and exclusivity dates are regulatory listings from the FDA Orange Book; no relationship to revenue or future sales is stated or implied.

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE · UNII not resolved · no lmmol compound match

Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.

Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.

Regulatory listing data as published by FDA; not medical or investment advice.